Anticoagulant Therapies and Heparin Monitoring

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

What is the biggest challenge associated with unfractionated heparin?

Need for continuous subcutaneous injection

High therapeutic index

Long half-life

Narrow therapeutic index (correct)

Which of the following is used to monitor the anticoagulant effects of continuous infusion unfractionated heparin?

INR

Antifactor Xa (correct)

Prothrombin time

Clotting time

Which laboratory measures should be monitored to determine if someone is bleeding while on unfractionated heparin?

APTT only

Platelet count only

INR only

Hemoglobin and hematocrit (correct)

What is a significant adverse effect of unfractionated heparin that necessitates monitoring?

Bleeding Signup and view all the answers

Which of the following factors can increase the risk of bleeding when a patient is on unfractionated heparin?

Antiplatelet drugs Signup and view all the answers

What is one of the three low molecular weight heparins (LMWH) available?

Dalteparin Signup and view all the answers

Which statement describes a difference between low molecular weight heparins and unfractionated heparin?

LMWH has a smaller side chain than UFH. Signup and view all the answers

What are the 4 T's used for diagnosing thrombocytopenia?

Thrombocytopenia, Timing, Thrombus, Other explanation Signup and view all the answers

What is the correct method of monitoring for low molecular weight heparins (LMWH)?

Anti-10 activity and serum creatinine Signup and view all the answers

Fondaparinux has a unique characteristic compared to other heparins. What is it?

It is a pentasaccharide with no tail. Signup and view all the answers

What is the primary method of action for Warfarin?

Racemic mixture of R and S isomers Signup and view all the answers

Which of the following is true regarding the dosing of dalteparin and tinzaparin?

Both are dosed in units of antifactor Xa activity. Signup and view all the answers

What is the primary laboratory value monitored in patients taking Warfarin?

International normalized ratio (INR) Signup and view all the answers

Which vitamin K dependent clotting factor has the shortest half-life?

Factor VII Signup and view all the answers

What should you do if a patient has a history of heparin-induced thrombocytopenia (HIT)?

Avoid LMWH or UFH. Signup and view all the answers

Which anticoagulant is considered safe for use during pregnancy?

Fondaparinux Signup and view all the answers

What does a high INR value indicate for a patient on Warfarin?

More anticoagulation and higher risk of bleeding Signup and view all the answers

When should Fondaparinux be discontinued?

When the CrCl falls below 30 mL/min Signup and view all the answers

When should INR monitoring occur for hospitalized patients starting Warfarin therapy?

On the 2nd day and then QD until in therapeutic range Signup and view all the answers

What is the starting dose of Warfarin typically recommended?

5 mg/day Signup and view all the answers

What is a major adverse effect (ADE) associated with the use of Fondaparinux?

Bleeding Signup and view all the answers

What is the main indication for using Fondaparinux?

Patients with HIT Signup and view all the answers

How frequently should patients check their INR once their dose of Warfarin is stabilized?

Every 4-6 weeks Signup and view all the answers

Why is a loading dose of Warfarin not typically recommended?

It does not lead to quicker anticoagulation effects Signup and view all the answers

Which direct oral anticoagulant (DOAC) is the most eliminated in the urine?

Dabigatran Signup and view all the answers

Which DOAC is preferred for patients with poor kidney function?

Apixaban Signup and view all the answers

What is the primary monitoring focus for patients on DOACs?

Bleeding events only Signup and view all the answers

Which of the following drug interactions is most likely to increase the risk of bleeding in patients taking warfarin?

A drug that is a CYP 1A2 inhibitor Signup and view all the answers

Which of the following DOACs are both substrates of P-glycoprotein?

Apixaban Signup and view all the answers

Which direct oral anticoagulant has the most interactions with CYP3A4?

Rivaroxaban Signup and view all the answers

What effect do leafy green vegetables have on warfarin therapy?

Decrease INR and bleeding risk Signup and view all the answers

Which of the following statements about warfarin-related bleeding is true?

Warfarin may worsen bleeding from pre-existing conditions Signup and view all the answers

Which CYP enzyme is primarily involved in the metabolism of warfarin and its interaction with phenytoin?

CYP 2C9 Signup and view all the answers

What is the relationship between warfarin dose and INR levels?

Higher warfarin doses increase INR Signup and view all the answers

Which medication is known to induce CYP enzymes and potentially decrease the effectiveness of warfarin?

Rifampin Signup and view all the answers

What is a potential adverse effect of warfarin therapy unrelated to bleeding?

Purple-toe syndrome Signup and view all the answers

If a patient is consuming a diet rich in vitamin K, what is the expected change in their INR levels during warfarin therapy?

Decrease in INR Signup and view all the answers

Study Notes

VTE Risk Factors

Individuals at moderate or high risk of developing VTE:
- Those who have recently undergone orthopedic & non-orthopedic surgery
- Medically ill patients

VTE Prevention - Orthopedic & Non-Orthopedic Surgeries

Drugs used:
- Unfractionated Heparin (UFH):
  - Route: Intravenous (IV)
  - Dose: Based on individual needs, typically adjusted to achieve a specific activated partial thromboplastin time (aPTT)
  - Frequency: Continuous infusion
- Low Molecular Weight Heparin (LMWH):
  - Route: Subcutaneous (SQ)
  - Dose: Varies depending on specific LMWH (Enoxaparin, Dalteparin, or Tinzaparin)
  - Frequency: Once or twice daily

VTE Prevention - Medically Ill Patients

Drugs used:
- Unfractionated Heparin (UFH):
  - Route: Intravenous (IV)
  - Dose: Based on individual needs, typically adjusted to achieve a specific aPTT
  - Frequency: Continuous infusion
- Low Molecular Weight Heparin (LMWH):
  - Route: Subcutaneous (SQ)
  - Dose: Varies depending on specific LMWH (Enoxaparin, Dalteparin, or Tinzaparin)
  - Frequency: Once or twice daily
- Fondaparinux (Arixtra):
  - Route: Subcutaneous (SQ)
  - Dose: Fixed-dose (2.5 mg once daily)
  - Frequency: Once daily
- Warfarin (Coumadin):
  - Route: Oral
  - Dose: Starting dose is typically 5 mg daily, adjusted to achieve a desired international normalized ratio (INR)
  - Frequency: Once daily
- Direct Oral Anticoagulants (DOACs):
  - Dabigatran (Pradaxa):
    - Route: Oral
    - Dose: Varies depending on indication
    - Frequency: Twice daily
  - Rivaroxaban (Xarelto):
    - Route: Oral
    - Dose: Varies depending on indication
    - Frequency: Once or twice daily
  - Apixaban (Eliquis):
    - Route: Oral
    - Dose: Varies depending on indication
    - Frequency: Once or twice daily
  - Edoxaban (Savaysa):
    - Route: Oral
    - Dose: Varies depending on indication
    - Frequency: Once daily

VTE Treatment

Drugs Used:
- Unfractionated Heparin (UFH):
  - Route: Intravenous (IV)
  - Dose: Based on individual needs, typically adjusted to achieve a specific aPTT
  - Frequency: Continuous infusion
  - Duration: Usually for initial treatment, then transitioned to other anticoagulation
- Low Molecular Weight Heparin (LMWH):
  - Route: Subcutaneous (SQ)
  - Dose: Varies depending on specific LMWH (Enoxaparin, Dalteparin, or Tinzaparin)
  - Frequency: Once or twice daily
  - Duration: Can be used for initial treatment or as a bridge to oral anticoagulants
- Fondaparinux (Arixtra):
  - Route: Subcutaneous (SQ)
  - Dose: Fixed-dose (2.5 mg once daily)
  - Frequency: Once daily
  - Duration: Can be used for initial treatment or as a bridge to oral anticoagulants
- Warfarin (Coumadin):
  - Route: Oral
  - Dose: Starting dose is typically 5 mg daily, adjusted to achieve a desired international normalized ratio (INR)
  - Frequency: Once daily
  - Duration: Typically continued for several weeks or months
- Direct Oral Anticoagulants (DOACs):
  - Dabigatran:
    - Route: Oral
    - Dose: Varies depending on indication
    - Frequency: Twice daily
  - Rivaroxaban:
    - Route: Oral
    - Dose: Varies depending on indication
    - Frequency: Once or twice daily
  - Apixaban:
    - Route: Oral
    - Dose: Varies depending on indication
    - Frequency: Once or twice daily
  - Edoxaban:
    - Route: Oral
    - Dose: Varies depending on indication
    - Frequency: Once daily
    - Duration: Typically for several weeks or months

Treatment of Massive Pulmonary Embolism (PE)

Candidates for initial thrombolytic therapy:
- Patients with hemodynamically unstable PE
- Those at high risk for death or long-term disability

Unfractionated Heparin (UFH)

Challenges:
- Narrow therapeutic index
- Requires frequent monitoring of anticoagulant effect

UFH Monitoring

Anticoagulant effects can be monitored using two factors:
- Antifactor Xa
- aPTT
Monitoring frequency:
- Measure aPTT or antifactor Xa level before initiation to determine baseline
- Then monitor every 6 hours after starting IV UFH
- Monitor using either aPTT or antifactor Xa, not both.

UFH Adverse Effects

Most concerning:
- Bleeding
Other common effects:
- Thrombocytopenia (low platelet count)
- Platelet monitoring is crucial for safety.

Factors Increasing Bleeding Risk with UFH

Medications contributing to bleeding risk with UFH:
- Antiplatelet drugs
- NSAIDs
- Other antithrombotic therapies

4 T's Used for Diagnosis of Heparin-Induced Thrombocytopenia (HIT)

Four T's:
- Thrombocytopenia
- Timing of platelet count fall
- Thrombosis
- Other explanation for falling platelets

Monitoring Overall Blood Loss (Bleeding) With UFH

Check hemoglobin and hematocrit levels
A drop in these levels may indicate blood loss somewhere in the body

Monitoring UFH Patients

Key monitoring parameters:
- aPTT or antifactor Xa efficacy
- Platelet count for safety
- Hemoglobin and hematocrit levels

Low Molecular Weight Heparins (LMWHs)

Difference from UFH:
- LMWHs have a smaller side chain, preventing them from binding to thrombin as tightly as UFH.
- They inhibit factor Xa more effectively than factor IIa (thrombin) due to their smaller side chain.

Available LMWHs

Commonly used LMWHs include:
- Enoxaparin (Lovenox)
- Dalteparin (Fragmin)
- Tinzaparin (Innohep)

Advantages of LMWH over UFH

LMWHs offer several advantages:
- More predictable anticoagulant dose response
- Improved subcutaneous bioavailability
- Dose independent clearance
- Longer half-life
- Better absorption

Dosing Differences Between LMWHs

Dosing for Enoxaparin is expressed in milligrams.
Dosing for Dalteparin and Tinzaparin is expressed in units of antifactor Xa activity.

Monitoring LMWH

Monitoring with LMWH is not typically necessary due to its predictable anticoagulant response, especially with SQ administration.
Baseline labs should be obtained, including:
- CBC with platelets
- Serum creatinine
Monitor:
- Anti-Xa activity
- Serum creatinine

LMWH Contraindications

LMWH use is contraindicated for patients with:
- A history of heparin-induced thrombocytopenia (HIT)

Monitoring Parameters for LMWH

Monitoring parameters for LMWH include:
- Anti-Xa
- aPTT does not inhibit factor IIa as effectively as UFH.

Timing of Monitoring for LMWH vs. UFH

Monitoring timing is different for LMWH and UFH:
- LMWH: Baseline, then 4 hours after
- UFH: Baseline, then 6 hours after

aPTT and LMWH

aPTT tells you nothing about the effectiveness of LMWH.
You must evaluate anti-Xa levels to assess effectiveness.

LMWH Side Effects

Common side effects of LMWH:
- Bleeding (less frequent compared to UFH)
- Epidural and spinal hematomas in patients with epidural catheters
- Thrombocytopenia, but it is important to avoid LMWH in patients with a history of HIT.
- LMWH is generally safe during pregnancy.

Fondaparinux

Characteristics of Fondaparinux:
- It's a pentasaccharide, not a heparin.
- Unlike heparin, it does not have tails, so it does not interact with thrombin.
Fondaparinux does not bind tightly to thrombin.
Fondaparinux inhibits factor Xa.
Unlike UFH and LMWH, Fondaparinux does not impact platelet function.

Main Indication for Fondaparinux

Patients with HIT

Fondaparinux Brand Name

Brand name: Arixtra

Fondaparinux Monitoring

Monitor:
- Hemoglobin, hematocrit, and kidney function (serum creatinine)
- Platelet monitoring is not necessary as it does not impact platelet function.

Administration Routes for Anticoagulants (SQ & IV)

SQ administration routes are commonly used with:
- LMWH
- Fondaparinux

Fondaparinux Dosing Frequency

Fondaparinux is dosed:
- Once daily

Summary of Anticoagulant Monitoring

UFH: Monitor aPTT or anti-Xa
LMWH: Monitor anti-Xa and serum creatinine
Fondaparinux: Monitor kidney function only, as it has stable pharmacokinetics.

Fondaparinux Safety in Elderly & Pregnant Patients

Fondaparinux is safe in elderly patients, but bleeding risk may increase with age.
It is also safe during pregnancy.

Most Common Adverse Effect of Fondaparinux

The most common adverse effect of Fondaparinux is:
- Bleeding

When to Discontinue Fondaparinux

Discontinuation of Fondaparinux use is recommended when:
- Creatinine clearance (CrCl) is less than 30 ml/min.

Warfarin

Warfarin requires:
- Continuous monitoring
- Patient education
- It has a narrow therapeutic index.
- It has many drug and food interactions.

Warfarin Mechanism of Action (MOA)

Warfarin is a racemic mixture of the R and S isomers:
- The S isomer is primarily metabolized by CYP2C9.
- The R isomer is metabolized by other enzymes, including CYP1A2 and CYP3A4.

Warfarin's Effect on Vitamin K-Dependent Clotting Factors

Warfarin inhibits the synthesis of vitamin K-dependent clotting factors:
- Factor VII
- Factor IX
- Factor X
- Factor II (prothrombin)
These factors have varying half-lives:
- Factor VII has the shortest half-life, measured in hours.
- Other factors have half-lives measured in days.

Monitoring Warfarin

Monitoring parameters for Warfarin:
- Prothrombin time (PT): NOT aPTT
- INR

Target INR for Most Warfarin Indications

The target INR for most indications:
- 2.5 (range: 2-3.0)

INR Interpretation

A high INR level indicates:
- Greater anticoagulation effect
- Higher bleeding risk.
A low INR level means:
- Insufficient anticoagulation
- Higher risk of clotting.

INR in Normal Individuals

The normal INR range:
- 1

Warfarin Monitoring Frequency

INR monitoring frequency:
- Hospitalized patients:
  - On the second day of initiation, then daily until INR is in the therapeutic range (2-3.0)
- Outpatients:
  - Twice during the first week of therapy

Warfarin Dose Adjustment

When the INR target range is achieved, adjust the dose as needed:
- Check INR weekly until stable, then every 4 to 6 weeks.
- After a dosage change, recheck in 1 week followed by weekly checks until INR stabilizes and then every 4-6 weeks.

Normal Warfarin Dose

A starting dose of 5 mg/day is common.
Lower doses are recommended for patients who are more prone to bleeding, including those with:
- Elderly age
- Poor nutrition
- Liver disease
- Genetic polymorphisms
- Concurrent medication interactions
- Elevated baseline INR

Loading Dose of Warfarin

There is no significant benefit of giving a loading dose of Warfarin, as it does not rapidly achieve anticoagulation.
While loading doses are FDA-approved, they don't make a significant difference for most people and are not recommended.

Warfarin Pharmacogenetics

Guidelines generally discourage routine pharmacogenetics testing for guiding warfarin doses.

Warfarin Drug Interactions

Drug-drug interactions can alter warfarin’s metabolism, impacting INR and bleeding risk:
- Drugs that inhibit or induce CYP2C9, CYP1A2, and CYP3A4 have the greatest potential for impacting INR and bleeding.
- Drugs affecting hemostasis or platelet function can increase bleeding risk without affecting INR.

Dietary Considerations with Warfarin

Pay attention to green leafy vegetables, which are high in vitamin K:
- Vitamin K counteracts warfarin's effect, reducing INR and increasing clot risk.

CYP Enzymes and INR

CYPs that increase INR (leading to greater anticoagulation):
- CYP inhibitors: 1A2, 2C9, 3A4
- This can result in more bleeding.
CYPs that decrease INR (leading to less anticoagulation):
- CYP inducers: Medications for seizures, such as phenytoin
- This can increase clot risk.

Impact of Green Leafy Vegetables on INR

High intake of green leafy vegetables (high in vitamin K) will likely lead to a decrease in INR.
This means the patient is at a higher risk for clotting.

Warfarin Adverse Effects

Warfarin does not directly cause bleeding; it exacerbates bleeding from pre-existing lesions.
Important to monitor for bleeding, which should not occur spontaneously in:
- Nose
- Gums
- Skin
- Urine
- Stool
- Teeth while brushing
- Vagina
- Gastrointestinal tract
Signs of blood in stool: pink, red, black, or tarry
Seek medical attention if bleeding occurs.

Warfarin Adverse Effects (cont.)

Other adverse effects of Warfarin:
- Purple-toe syndrome
- Warfarin-induced skin necrosis

Direct Oral Anticoagulants (DOACs)

DOACs directly inhibit thrombin or factor Xa without requiring any cofactors:
- Dabigatran (Pradaxa): Direct thrombin inhibitor
- Rivaroxaban (Xarelto), Apixaban (Eliquis), and Edoxaban (Savaysa): Factor Xa inhibitors

DOAC Drug Interactions

Drug-drug interactions with DOACs:
- Dabigatran is primarily eliminated through the kidneys and is most susceptible to changes in kidney function, making kidney function monitoring crucial.
- Apixaban is the least renally eliminated and is often used in people with kidney problems.
- Rivaroxaban has the most interactions with CYP3A4 enzymes, followed by Apixaban.
- All DOACs are substrates of P-glycoprotein, and some interactions with P-glycoprotein inducers and inhibitors can impact their efficacy.

DOAC Monitoring

Monitoring for DOACs:
- Monitor for bleeding as the primary concern
- Renal function and hemoglobin/hematocrit can also be monitored.

DOAC Selection for Patients with Kidney Disease

For patients with poor kidney function, consider:
- Apixaban

DOACs and CYP3A4/P-gp Metabolism

DOACs that are substrates of CYP3A4 and P-glycoprotein:
- Rivaroxaban
- Apixaban
DOACs that are NOT significantly metabolized by CYP3A4 but are P-glycoprotein substrates:
- Edoxaban
- Dabigatran
Important P-glycoprotein inhibitors:
- Amiodarone
- Propafenone
- Quinidine
- Verapamil
Important P-glycoprotein inducers:
- Carbamazepine
- Rifampin

Studying That Suits You

Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

Description

This quiz explores various aspects of anticoagulant therapies, focusing on unfractionated heparin and low molecular weight heparins (LMWH). Questions cover monitoring techniques, potential adverse effects, and comparisons between heparins. Test your knowledge on critical anticoagulation management and safety measures.